Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization

Award Number: R01AI176563
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2023
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization - Project Abstract/Summary • Our framing hypothesis is that the combined constraints of peptide processing, HLA allelic specificity, and peptide editing generate a significant “funnel effect”, where the peptidome constitutes only a tiny percentage of all possible peptides obtainable from a cell’s proteome and the ligandome constitutes only a small percentage of all peptides from a cell’s peptidome. Our research focus is understanding how the interplay of differential sequence recognition at each step ultimately informs functional presentation of a highly restricted subset of all possible proteome-derived peptides – and how to identify the most “translatable” pHLA targets from ligandomes. • We will rigorously test this hypothesis using our allele-specific mass-spec platform for peptide discovery, ARTEMIS, to identify relevant, HLA-restricted peptides from Mesothelin and high-risk HPV E6/E7 oncoproteins. Identified peptides will be validated and characterized biochemically. Cell-surface displayed peptide arrays from E6/E7 and Mesothelin will be used to determine the magnitude of the “funnel effect” of peptide processing on peptidome composition. Patient T cell responses to identified Mesothelin peptides will be mapped using state- of-the-art methodologies. Unusual peptides and alternate binding conformations will be characterized crystallo- graphically. We will assess viral immunoevasion mechanisms, HLA-G presentation and receptor interactions, and the presentation of glycosylated peptides. Deliverables include mapping the full Mesothelin and E6/E7 presentomes across multiple alleles and presentation modalities, ranked for future clinical exploitation as immu- notherapy targets. • Significance: From a basic science perspective, assaying cellular peptidomes and ligandomes is fundamental for understanding how the immune system responds to infections and cancer, immunoevasion mechanisms, the recognition rules of MHC proteins, the mechanistics of antigen processing/editing, and how self is defined. From a translational perspective, validated HLA-restricted peptides represent targets for diagnosis and therapy, through therapeutic vaccination, engineered T cell-based adoptive immunotherapies, and antibody-based recog- nition of specific, disease-associated peptide/HLA complexes Our proposed studies advance both objectives by elucidating the underlying molecular principles governing peptide processing and presentation through inte- grated studies of an extended set of classical and non-classical human HLA class I proteins and, in the process, identify specific pHLAs useful for future clinical applications.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $804,206 )
2026	2026	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	4	1/17/2026	NON-COMPETING CONTINUATION	$804,206
														Subtotal = $804,206

Issue Date FY: 2025 ( Subtotal = $780,080 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	3	1/21/2025	NON-COMPETING CONTINUATION	$780,080
														Subtotal = $780,080

Issue Date FY: 2024 ( Subtotal = $804,206 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	2	2/16/2024	NON-COMPETING CONTINUATION	$723,785
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	2	5/23/2024	NON-COMPETING CONTINUATION	$80,421
														Subtotal = $804,206

Issue Date FY: 2023 ( Subtotal = $804,206 )
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	1	1/30/2023	NEW	$804,206
														Subtotal = $804,206

Grand Total All Awards = $3,192,698

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization

Award Number: R01AI176563

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2023

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer